Mobile Origins, a TTP Firm, targeted on enabling scalable, cost-effective, and environment friendly manufacture of cell and gene therapies (CGTs), at the moment introduced the appointment of Geoffrey Hodge to its Board as Non-Govt Director (NED). Leveraging intensive experience, data and expertise in cell remedy and biomanufacturing, Geoff’s appointment will strengthen the Firm’s strategic imaginative and prescient and technical functionality to ship accelerated development and continued business success.
Geoff was most lately CEO of SOTIO Biotech US and CTO of Unum Therapeutics, each autologous cell remedy corporations. Previous to coming into the cell remedy sector, Geoff co-founded Xcellerex, the place he was the first inventor of the XDR single-use bioreactor and head of the CDMO biomanufacturing providers enterprise, which helped the corporate develop to $50M in income previous to its acquisition by GE Healthcare.
Along with his function on the Board of Mobile Origins, Geoff will stay a part of the Firm’s Scientific Advisory Board, the place his intensive expertise in growing biomanufacturing know-how and confirmed business success has already helped to form the Firm’s strategic route. As NED, Geoff will work carefully alongside the Board and management crew to speed up development and guarantee continued growth of the Firm’s robotic platform for cost- and space-efficient manufacture of cell therapies, Constellation™.
Mobile Origins lately acquired IP to the ACTIA (Autologous Cell Remedy Industrial Automation) Platform developed by Geoff while he was at SOTIO Biotech1.
Dr Edwin Stone, CEO at Mobile Origins, stated: “Geoff has distinctive expertise having constructed companies which have remodeled bioprocess manufacturing. There are only a few people who’ve been by way of this journey. At Mobile Origins, we all know how necessary it’s to our prospects that we are able to ship options they’ll depend on and belief for the manufacturing of necessary therapies. Geoff’s experience in constructing a enterprise that was profitable in doing this will probably be invaluable to Mobile Origins. His steering, technical and business perception and {industry} community are, and can proceed to be, an important asset as we realise our ambition to realize sooner, cost-effective and environment friendly routes to scalable manufacture of cell therapies.”
Geoffrey Hodge, Non-Govt Board Director, Mobile Origins, commented: “Mobile Origins affords a transformative, industry-ready resolution that addresses the challenges of producing cell therapies at scale. I look ahead to becoming a member of the Board and additional deepening my involvement within the Firm at this thrilling time in its growth and development.”
